Margaret Horn Sells 4,847 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 4,847 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total value of $372,346.54. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares of the company’s stock, valued at approximately $10,835,691.46. This represents a 3.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $78.78 on Friday. The company has a market capitalization of $15.23 billion, a price-to-earnings ratio of -15.24 and a beta of 0.96. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $81.49. The company’s 50-day moving average is $66.73 and its 200 day moving average is $49.21.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period last year, the firm earned ($0.94) EPS. Sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently made changes to their positions in the company. CWM LLC lifted its stake in shares of Revolution Medicines by 171.3% in the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after purchasing an additional 579 shares during the period. GAMMA Investing LLC increased its holdings in Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after buying an additional 260 shares during the last quarter. Banque Transatlantique SA bought a new position in Revolution Medicines in the first quarter worth approximately $42,000. Quarry LP bought a new position in Revolution Medicines in the first quarter worth approximately $50,000. Finally, Twin Tree Management LP purchased a new position in shares of Revolution Medicines during the 1st quarter worth $58,000. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RVMD shares. UBS Group upgraded Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. HC Wainwright boosted their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. upped their target price on shares of Revolution Medicines from $71.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Wells Fargo & Company raised their price target on shares of Revolution Medicines from $67.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Finally, National Bankshares set a $80.00 price objective on shares of Revolution Medicines in a report on Friday, October 17th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $78.50.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.